Keryx Biopharmaceuticals (KERX): Rare Diseases and Rare Drugs Could Mean Great Gains For You

Page 2 of 2

With the goal to develop therapies for rare disease, it is expected that Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s CDX-110 will generate $8.87 million in 2016, $47.74 million in 2017, and expects peak sales potential of $500 million in the long run.

Conclusion

Keryx Biopharmaceuticals (NASDAQ:KERX)’s Zerenex will be used for treating Hyperphosphatemia in ESRD patients and non-dialysis CKD patients, which will eventually result in high annual savings.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)’s IPI-504 and IPI-145 have a strong global market potential as they are drugs for treating rare blood cancers and NSCLC.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s goal to develop drugs for rare diseases with CDX-011 and CDX-110 has shown positive results in the trials. With the strong market potential for rare drugs, the company can generate high revenue.

Therefore, I recommend a Buy for all three stocks.

The article Rare Diseases and Rare Drugs Could Mean Great Gains For You originally appeared on Fool.com.

Madhukar Dubey has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Madhukar is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2